Do cervical cancer data justify human papillomavirus vaccination in India? Epidemiological data sources and comprehensiveness

Forman, David; Franceschi, Silvia; Sankaranarayanan, Rengaswamy; Bray, Freddie; Ferlay, Jacques; Dikshit, Rajesh; Jha, Prabhat; Wild, Christopher P.

doi:10.1258/jrsm.2012.120207

Search citation statements

Order By: Relevance

Paper Sections

Select...

Adoptive Cell Therapy (Act)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIKs showed an increased cytotoxic effect and proliferative response [95 -102]. Despite several biases of the clinical trials, 2 meta-analyses of CIK cell therapies [103,104] have reported higher recurrence free survival and overall survival rates in an adjuvant setting. A landmark study using autologous lymphocytes that were tumor-unspecifically expanded in vitro with IL-2 and anti-CD-3 revealed a significantly longer time to first recurrence after resection and significantly longer recurrence-free survival [105].…”

Section: Adoptive Cell Therapy (Act)mentioning

confidence: 99%

Perspectives of immunotherapy in hepatocellular carcinoma (HCC)

Büttner¹,

Schmidt²,

Thimme³

2016

Z Gastroenterol

View full text Add to dashboard Cite

Immunotherapy is considered a new treatment option for many tumor entities, as decades of research into cancer immunotherapy have recently yielded promising results. Indeed, impressive clinical results of checkpoint blockade inhibitors in malignant melanoma and non-small cell lung cancer indicate the therapeutic potential of tumor-specific immune restoration. Over the years, different immunotherapeutic approaches have been evaluated for the treatment of hepatocellular carcinoma (HCC) with some respectable results. In this review article, we will summarize the key studies of the past 30 years and will elucidate in which direction the dynamic field of HCC immunotherapy is currently moving.

show abstract

Section: Adoptive Cell Therapy (Act)mentioning

confidence: 99%